The Increasing Problem of Resistant Hypertension: We’ll Manage till Help Comes!
Medical Sciences · 04.10.2024 · 12 (4) · 53
DOI: 10.3390/medsci12040053 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Medical Sciences, online erschienen am 04.10.2024. Verfasst von Francesco Natale und 8 weiteren Autor:innen. Beteiligte Einrichtung: Vanvitelli Cardiology and Intensive Care Unit, Monaldi Hospital, 80131 Naples, Italy. Hauptthemen laut MEDLINE: Hypertension, Antihypertensive Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 91 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Arterial hypertension remains the major cardiovascular risk worldwide. It is estimated that under 50 years of age one in every three adults is hypertensive while beyond the age of 50 the prevalence is almost 50% globally. The latest World Health Organization (WHO) Global Report on Hypertension indicated that the global number of hypertensive patients almost doubled in the last three decades, with related increasing deaths, disability, and costs annually. Because of this global increase, early diagnosis and timely treatment is of great importance. However, based on the WHO Global Report, it is estimated that up to 46% of individuals were never diagnosed. Of those diagnosed, less than 50% were on treatment, with nearly half among these at target according to the current guidelines. It is also important to note that an increasing number of hypertensive patients, despite the use of three or more drugs, still do not achieve a blood pressure normalization, thus defining the clinical scenario of resistant hypertension (RH). This condition is associated to a higher risk of hypertension-mediated organ damage and hospitalization due to acute cardiovascular events. Current guidelines recommend a triple combination therapy (renin angiotensin system blocking agent + a thiazide or thiazide-like diuretic + a dihydropyridinic calcium-channel blocker) to all patients with RH. Beta-blockers and mineralocorticoid receptor antagonists, alone or in combination, should be also considered based on concomitant conditions and potential contraindications. Finally, the renal denervation is also proposed in patients with preserved kidney function that remain hypertensive despite the use of maximum tolerated medical treatment. However, the failure of this procedure in the long term and the contraindication in patients with kidney failure is a strong call for a new therapeutic approach. In the present review, we will discuss the pharmacological novelties to come for the management of hypertension and RH in the next future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Vanvitelli Cardiology and Intensive Care Unit, Monaldi Hospital, 80131 Naples, Italy.
- Department of Translational Medical Sciences, Section of Cardiology, University of Campania Luigi Vanvitelli, 80131 Naples, Italy.
- Cardiology Unit, AOU Luigi Vanvitelli, 80138 Naples, Italy.
ORCID-Profile: Francesco Natale, Saverio D'Elia, Paolo Golino, Giovanni Cimmino
Zitieren
APA
Natale, F., Franzese, R., Luisi, E., Mollo, N., Marotta, L., Solimene, A., D'Elia, S., Golino, P., & Cimmino, G. (2024). The Increasing Problem of Resistant Hypertension: We’ll Manage till Help Comes!. Medical Sciences, 12(4), 53. https://doi.org/10.3390/medsci12040053
Vancouver
Natale F, Franzese R, Luisi E, Mollo N, Marotta L, Solimene A, et al. The Increasing Problem of Resistant Hypertension: We’ll Manage till Help Comes!. Medical Sciences. 2024;12(4):53. doi:10.3390/medsci12040053
BibTeX
@article{Natale2024,
author = {Natale, Francesco and Franzese, Rosa and Luisi, Ettore and Mollo, Noemi and Marotta, Luigi and Solimene, Achille and D'Elia, Saverio and Golino, Paolo and Cimmino, Giovanni},
title = {The Increasing Problem of Resistant Hypertension: We’ll Manage till Help Comes!},
journal = {Medical Sciences},
year = {2024},
volume = {12},
number = {4},
pages = {53},
doi = {10.3390/medsci12040053}
}
EUVIMED